Internship
Posted on 10/11/2023
Develops and delivers biopharmaceutical medicines
Company Historically Provides H1B Sponsorship
Princeton, NJ, USA
You match the following Bristol Myers Squibb's candidate preferences
Employers are more likely to interview you if you match these preferences:
Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing access to effective and affordable healthcare solutions.
Company Size
10,001+
Company Stage
IPO
Total Funding
$33.7B
Headquarters
New York City, New York
Founded
1887
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- Nanomosaic, a leader in multiplex, multi-omic marker analysis, today announced the publication of a scientific white paper detailing a study conducted with Bristol Myers Squibb (BMS). The paper explores the potential of the nanoneedle technology as an innovative tool for enhancing the depth and breadth of insights into AAV (adeno-associated virus) manufacturing processes and product quality. During AAV production, natural variations in the viral genome lead to the formation of subpopulations within a single batch. These variations can negatively impact the efficiency of the vector, potentially compromising therapeutic efficacy or causing unintended side effects due to suboptimal AAV subpopulations. To mitigate these risks, AAV developers and manufacturers implement strategies to selectively enrich preparations with particles containing a complete transgene capable of delivering the desired therapeutic effect
Bristol Myers Squibb is planning another round of cost cutting initiatives.On Thursday, the Princeton-based firm said it plans to find $2 billion in additional savings over the next three years, on top of the $1.5 billion in cuts it announced in April 2024. The company has been looking to improve its efficiency by reducing clinical trial expenses, rationalizing its operating footprint and reducing its head count.The new reductions will come in two major categories: cuts to the workforce, including contract positions, open roles and attrition. The second set is made up of operating costs such as marketing spending on older drugs, clinical trial operations and supply chain items like manufacturing facilities and outside contractors.BMS’ latest workforce reduction affects 67 employees in Lawrence Township, according to a New Jersey Worker Adjustment and Retraining Notification (WARN) notice. The notice lists several effective dates for the cuts stretching into December.BMS is expected to dismiss more than 2,000 employees in total as part of the overhaul. Last year alone, BMS filed six WARN notices affecting a total of 1,329 staffers in Lawrenceville, which hosts the company’s sprawling corporate headquarters and a Princeton Pike facility for commercial and late-stage development functions
Why is Bristol-Myers Squibb Company (BMY) among the Best High-Yield Dividend Stocks to Invest In?
Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The r
New Initiative in Partnership with Africa Centers for Disease Control (Africa CDC) and Local Ministries of Health Builds on Decades of Capacity Building to combat HIV and Pediatric CancerHOUSTON, Jan. 17, 2025 /PRNewswire/ -- Texas Children's Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in their joint efforts to dramatically improve children's health in Sub-Saharan Africa with the launch of a groundbreaking program to address one of the most urgent threats facing the region: sickle cell disease (SCD)